← Back to Search

Sodium Channel Blocker

Ranolazine 500mg for Lou Gehrig's Disease

Phase 2
Waitlist Available
Led By Jeffrey Statland, MD
Research Sponsored by University of Kansas Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, weeks 2, 6, and 8
Awards & highlights

Study Summary

This trial will study whether Ranolazine is safe and effective for treating ALS patients.

Eligible Conditions
  • Lou Gehrig's Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, weeks 2, 6, and 8
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, weeks 2, 6, and 8 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Dose limiting toxicities (DLT)
Secondary outcome measures
Cramp Questionnaire
Cramp potential duration
Fasciculation frequency on muscle ultrasound

Trial Design

2Treatment groups
Experimental Treatment
Group I: Ranolazine 500mgExperimental Treatment1 Intervention
Participants will take Ranolazine 500mg twice daily for up to 4 weeks.
Group II: Ranolazine 1000mgExperimental Treatment1 Intervention
Participants will take Ranolazine 1000mg twice daily for up to 4 weeks.

Find a Location

Who is running the clinical trial?

University of Kansas Medical CenterLead Sponsor
462 Previous Clinical Trials
169,187 Total Patients Enrolled
Gilead SciencesIndustry Sponsor
1,084 Previous Clinical Trials
848,459 Total Patients Enrolled
Jeffrey Statland, MDPrincipal InvestigatorUniversity of Kansas Medical Center
4 Previous Clinical Trials
1,064 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis
Jeffrey Statland 2018. "Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03472950.
All > Lou Gehrigs Disease > Ranolazine
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top